Seeking Freelance OC, Calif Med Device Social Media Marketer

Leading, global medical device corporation in Orange County CA is seeking a full-time social media & PR/marcomm freelancer for an onsite, 8 week assignment, starting in June 2012. Details are below. If interested, please email Deb Kaufman directly with your resume and med device experience, at erxhealthcare@hotmail.com

Full information is below.

TITLE: Social Media & Marketing Communications/PR Manager - Full Time Freelancer

EMPLOYER: Medical Device Corporation (global, publicly traded)

LOCATION: Orange County, CA

REPORTS TO: VP Marketing

FREELANCE OPPORTUNITY, 8 weeks, starting ASAP/June 2012

TO APPLY: email resume that details any/all medical device social media/digital strategies & PR/marcomm experience to: Deb Kaufman erxhealthcare@hotmail.com

THE POSITION

Eight week onsite full-time opportunity for a skilled integrated communications and social media/digital strategies practitioner who is a self-starter, independently accountable and able to drive projects from inception to completion.

Freelancer should possess well-honed skills in the full range of PR/communications strategies and tactics (press releases, media relations, collateral development, sales management support programs) with a strong focus on developing/integrated compelling social media and interactive strategies and solutions. This professional will be a strategic thinker who understands social media’s role and impact, and will have demonstrated experience in the development and execution of social media campaigns/online marketing.

The Freelancer will have a passion for innovation and delivering broad-based PR/strategic communications and digital marketing solutions; will be a strong writer, able to develop compelling social media content; and are as hands-on as they are creative/strategic. A supreme project management orientation is essential as well as an ability to instill trust and confidence across a wide variety of programs and with multiple department contacts.

THE RESPONSIBILITIES

Includes, but not limited to the following:

Ÿ  Lead/own projects; independently accountable

Ÿ  Develop, oversee and manage sophisticated PR, communications and social media/digital projects

Ÿ  Develop and execute online strategies, including writing strategic and creative content and researching competitors

Ÿ  Monitor, measure and report performance on builds and campaigns; regularly monitor and create ROI and performance reports for PR, communications and social media

Ÿ  Understand basic research techniques and methodologies and use them to support development/execution of campaigns

Ÿ  Exhibit strong understanding of the PR/communications, digital landscape, and online measurement and analytics

Ÿ  Design and implement directly or through vendors relationships, online advocacy efforts

Ÿ  Monitor PR and social media channels on a daily basis for latest trends and case studies; and maintains a deep knowledge of social media channels and effective strategies to maximize engagement of online audiences

Ÿ  Train/educate marketing members on social media channels and best practices; strategize with and educate the management team and others across the company on incorporating relevant social media techniques into the corporate culture and into all of the company’s products and services

THE ESSENTIALS

Education:

Bachelors degree in marketing, communications or related field is preferred

Experience:

Ÿ  3-5+ years PR, marketing or advertising agency experience; interactive and social media/digital strategies a must; medical device experience strongly preferred

Ÿ  Must exhibit a demonstrated track record of developing and executing successful PR/media relations, online marketing and social media programs, and have knowledge of monitoring and analytical tools with an ability synthesize data

Ÿ  Comprehensive understanding of online marketing (including social and new media), email marketing and website functionality

Ÿ  Excellent interpersonal and communications skills, verbal and written

Ÿ  Superior organizational skills and attention to detail

Ÿ  Must be able to multi-task; strong project management skills; and able to manage multiple projects at a time

Ÿ  Passion for healthcare industry.

COPD Tops Asthma as the Focus Indication for Next Gen Respiratory Therapies

COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference Conference highlights include Novartis' highly anticipated NVA237 GLOW2 data and the rise of Pearl Therapeutics in the COPD market race; pivotal RELOVAIR results notably absent. Full press release below. SOURCE: Citeline NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's Analyst in Autoimmune/Inflammation. (Photo: http://photos.prnewswire.com/prnh/20120531/NE16127-INFO ) In the absence of results from GlaxoSmithKline and Theravance's market-leading RELOVAIR program, top COPD trials data presented at the conference include results from Novartis' Phase III NVA237 GLOW2 trial and final Phase II data from Boehringer Ingelheim's olodaterol monotherapy program. Both drugs provided significant improvement in bronchodilation with once-daily dosing, and these studies supported the dose selections for their respective FDC trials. Mid-sized companies Almirall and Forest showed sustained success of their partnered aclidinium bromide drug program, while privately-held Pearl Therapeutics divulged eight clinical publications at ATS, revealing statistically significant efficacy results and future plans for their LAMA/LABA (glycopyrrolate+formoterol fumarate), PT003. "The presentations at ATS this year provide further evidence of high competition to launch next generation FDC respiratory drugs. COPD has superseded asthma as the lead indication in the market race, most likely due to the FDA's new safety controls pertaining to limited use of all LABA-containing drugs in asthma as well as the unmet need for improved therapies for COPD," states Ms. Stacey, "Additionally, it appears that most companies are strategically conducting trials to launch their novel LAMA or LABA as monotherapy in advance of the registration of the associated FDC product." Despite the notable omission of pivotal RELOVAIR trial data from this year's ATS proceedings, GSK and Theravance continue to be the trailblazers in the race to launch the next generation COPD therapy through their partnership in two key FDC programs, RELOVAIR (fluticasone furoate+vilanterol) and their LAMA/LABA combination ('719+vilanterol). With the patent expiry of Advair in 2011 and the looming expiration of Symbicort later this year, GSK has positioned itself as the front runner in capturing a large share of the future respiratory market with these two strong Phase III FDC drug programs and plans to submit regulatory RELOVAIR applications for COPD in the US and Europe in mid-2012.  However, several competitors are riding on their heels, including Boehringer Ingelheim, Novartis, Almirall/Forest, and the up-and-coming Pearl Therapeutics, with strong FDC candidates in their pipelines. "Pearl Therapeutics is only in planning stages for their Phase III FDC program and is certainly the underdog among the current competition, but their innovative PT003 product had stellar Phase II data at ATS and they announced plans for PT010, a triple combination therapy of LAMA (glycopyrrolate), LABA (formoterol fumarate), and an inhaled corticosteroid, in one of their presentations," comments Ms. Stacey. "They will be an exciting company to watch as competitors in the FDC respiratory market race cross the finish line for novel inhaled therapies in COPD." About Citeline Citeline (www.citeline.com)  provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 20,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors. Media Invitation Members of the media interested in receiving a review of Citeline as well as further insight into our assessment of ATS 2012 should contact Julie McKenna at 617.415.1981 - or e-mail atJulie.mckenna@citeline.com. All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Julie McKenna Citeline Marketing Manager 617. 415.1981 SOURCE Citeline Web Site: http://www.citeline.com

FDA News: FDA Clearance, MRI-Guided Radiation Therapy System

ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System. Company Reaches Significant Milestone in Development of Integrated Medical Imaging and Radiation Therapy Technology.

Full press release below.

SOURCE: ViewRay Incorporated

CLEVELAND, May 30, 2012 /PRNewswire/ -- ViewRay™ Incorporated, a privately held medical device company, has received U.S. FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system. The ViewRay system features a unique combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance in 2011.

"FDA clearance of our integrated system is a major milestone in the development of our technology," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "It has already been an exciting year for ViewRay, with an additional round of funding and the installation of our first research systems at major U.S. medical centers. Early clinical imaging studies have verified the quality of the system's MR images, and now we're looking forward to clinical applications." The ViewRay system provides continuous soft-tissue imaging during treatment so that clinicians can see and record precisely where radiation therapy is being delivered, as it's being delivered.

ViewRay's patented cancer treatment technology was invented by company founder James F. Dempsey, PhD, while he was a member of the radiation oncology faculty at the University of Florida. "ViewRay began with the idea that we need to see what exactly we're doing when we treat cancer patients with radiation therapy," said Dempsey, now ViewRay's chief scientific officer. "Thanks to our clear vision, an outstanding engineering team, and dedicated leadership, we're now able to bring that idea into the clinic, where it can help cancer patients."

ViewRay recently closed the final tranche of a $45 million round of Series C venture capital financing intended to advance the ViewRay system toward commercialization. The first ViewRay system is installed at the Siteman Cancer Center at Barnes‐Jewish Hospital and Washington University School of Medicine, where early imaging studies have taken place. Additional ViewRay partners include the UCLA Jonsson Comprehensive Cancer Center and the University of Wisconsin Carbone Cancer Center, where a ViewRay system is currently being installed.

About ViewRay

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

ViewRay is a trademark of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

SOURCE ViewRay Incorporated

CONTACT: Michael Brandt, Senior Vice President, Sales, ViewRay Incorporated, +1-440-703-3210, ext. 200, media@viewray.com

Web Site: http://www.viewray.com 

NDA Submitted for Regorafenib

New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer. Full press release below. SOURCE: SOURCE Onyx Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., May 23, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (mCRC).  Regorafenib is a Bayer compound, and Onyx will receive a royalty on global net sales of regorafenib in oncology. The submission is based on the results of the pivotal, global Phase 3 CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. Results from the study were first presented at the Annual Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) in January 2012 and will be presented at the upcoming ASCO annual meeting inChicago, IL (USA) in early June 2012. Bayer has also submitted an application for European marketing authorization for regorafenib for the treatment of patients with mCRC. About the CORRECT Study  The CORRECT study was an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 760 patients with mCRC whose disease had progressed during or within 3 months following last administration of approved standard therapies.[i] Patients who had withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease were also allowed into the study. Patients were randomized to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Treatment cycles consisted of 160 mg of regorafenib (or matching placebo) once daily for three weeks on / one week off plus BSC. [ii] The study was conducted in North America, Europe, China, Japan and Australia. About Colorectal Cancer Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or rectum. The majority of cancers occurring in the colon and rectum are adenocarcinomas, which account for more than 90 percent of all large bowel tumors.[iii] CRC is the third most commonly diagnosed cancer and the third leading cause of cancer death in the United States, in both men and women.[iv]  It is estimated that more than 140,000 people will be diagnosed with CRC in 2011, and nearly 50,000 people will die from the disease.[v] Approximately 50 percent of colon cancer patients will be diagnosed with metastases (most commonly to the liver) either at the time of diagnosis or due to recurrent disease.[vi] About Regorafenib Regorafenib is an investigational oral multi-kinase and is currently being investigated in clinical trials for its potential to treat patients with various tumor types. Regorafenib is an investigational agent and is not approved by the FDA, EMA or other health authorities.  Regorafenib is one of several cancer compounds in Bayer's development pipeline. In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, Inc., under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology. About Onyx Pharmaceuticals, Inc. Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com. This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding the potential expansion of Onyx's product portfolio, the possibility of royalty payments to Onyx from the sale of regorafenib, and the timing, progress and results of clinical development and the regulatory approval process. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for Kyprolis (carfilzomib) or regorafenib; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; if approved, we or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for Kyprolis or regorafenib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, regorafenib or Kyprolis; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2011filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law. [i] A. Grothey, et al. Results of a randomized Phase 3 trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC who have progressed after standard therapies [January 17, 2012 ASCO-GI Presscast Presentation]. 2012 Gastrointestinal Cancers Symposium; January 19-21, 2012. San Francisco, CA. [ii] American Cancer Society. Colorectal Cancer Guide. Available from:http://www.cancer.org/acs/groups/cid/documents/webcontent/003096-pdf.pdf. Accessed on October 14, 2011. [iii] American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Available at:http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed on October 24, 2011. Accessed on October 14, 2011. [iv] American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Available at:http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed on October 24, 2011. [v] National Cancer Institute. Colon and Rectal Cancer. Available at:http://www.cancer.gov/cancertopics/types/colon-and-rectal. Accessed on October 24, 2011. [vi] National Cancer Institute. Stage IV and Recurrent Colon Cancer. Available at:http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page9. Accessed on October 24, 2011. SOURCE Onyx Pharmaceuticals, Inc. CONTACT: investors, Amy Figueroa, Senior Director, Investor Relations, +1-650-266-2398, or media, Lori Melancon, Senior Director, Corporate Communications, +1-650-266-2394, both of Onyx Pharmaceuticals, Inc. Web Site: http://www.onyx.com

To see more releases from Onyx Pharmaceuticals, Inc., Click Here

This company's web site http://www.onyx-pharm.com

SAE-AS PR Health Care

Revive Health was recently named top 2012 PR Boutique Agency of the Year by PRWeek. Open position is listed below.

POSITION: Senior Account Executive (SAE)/Account Supervisor (AS)

SECTOR: Health Services & HCIT (health care information technology)

AGENCY: Revive Health - www.revivepr.com

LOCATION: Nashville, TN or Santa Barbara, CA. Relocation Provided

YEARS EXPERIENCE: SAE (3-5 years); AS (5-7+ years). Prior PR agency experience required.

REPORTS TO: VP/SVP

TO APPLY: email resume in strict confidence to Deb Kaufman, deborah@healthcare-recruiting.com

THE POSITION

A Senior Account Executive (SAE)/Account Supervisor (AS) at Revive is a skilled integrated communications and social media practitioner who is a self-starter, independently accountable and able to drive projects from inception to completion. The SAE/AS coaches junior level account staff on best practices; and provides clients with strategic and tactical counsel that relies on PR, engagement marketing, and reputation management to achieve clients' business goals.

Revive's clients are hospitals and health systems, physicians and health IT companies, wellness and health services companies of all stripes.

An SAE/AS possesses well-honed skills in the full range of PR/communications strategies and tactics (press releases, media relations, collateral development, issues management/ grassroots programs) with a strong focus on developing/integrated compelling social media and interactive strategies and solutions for our clients. A supreme project management orientation is essential as well as an ability to instill trust and confidence across a wide variety of programs and with multiple client contacts. SAEs have the skills and the desire to share and teach digital/social media & media relations best practices internally to keep Revive on the cutting edge, for itself and for clients.

THE RESPONSIBILITIES

Includes, but not limited to the following:

Ÿ  Provide strategic and tactical counsel to clients that achieves clients' business goals

Ÿ  Helps to grow and maintain client relationships. Serve as primary day-to-day contact with clients

Ÿ  Lead/own projects; independently accountable

Ÿ  Coach, mentor and project-manage junior team members; collaborate with team members to deliver strategic, creative PR, strategic communications, issues management and social media and digital communication engagements for clients

Ÿ  Handle regular and consistent contact with clients; troubleshoot client issues

Ÿ  Develop, oversee and manage complex PR, communications and social media/digital projects

Ÿ  Develop and execute online strategies, including writing strategic and creative recommendations and researching competitors

Ÿ  Monitor, measure and report performance on builds and campaigns; regularly monitor and create ROI and performance reports for PR, communications and social media clients

Ÿ  Understand basic research techniques and methodologies and use them to support development/execution of client campaigns

Ÿ  Exhibit strong understanding of the PR/communications, digital landscape, and online measurement and analytics

Ÿ  Design and implement directly or through vendors relationships, online advocacy efforts in support of client engagements

Ÿ  Monitor PR and social media channels on a daily basis for latest trends and case studies; and maintains a deep knowledge of social media channels and effective strategies to maximize engagement of online audiences

Ÿ  Train/educate team members and clients on how to use social media channels and best practices; strategize with and educate the management team and others across the company on incorporating relevant social media techniques into the corporate culture and into all of the company’s products and services

THE ESSENTIALS

Education:

Bachelors degree in marketing, communications or related field is preferred

Experience:

Ÿ  3-5 years (SAE), 5-7+ years AS; PR, marketing or advertising agency experience (non-traditional, interactive and social media/digital strategies a must; health services/health care experience required

Ÿ  Experience in health services/hospital marketing, social media & public relations is strongly preferred

Ÿ  Must exhibit a demonstrated track record of developing and executing successful PR/media relations, online marketing and social media programs, and have knowledge of monitoring and analytical tools with an ability synthesize data

Ÿ  Comprehensive understanding of online marketing (including social and new media), email marketing and website functionality

Ÿ  Excellent interpersonal and communications skills, verbal and written

Ÿ  Superior organizational skills and attention to detail

Ÿ  Must be able to multi-task; strong project management skills; and able to manage multiple projects at a time

Ÿ  Passion for wellness and healthy lifestyle preferred

The Qualities and Attributes You Need to Succeed:

-     A drive to win and a focus on results

-     A love of PR and issues management

-     An “addiction” to quality thinking and performance

-     A commitment to personal mastery

-     An attitude of team abundance and a sense of humor

-     A genuine care for others

-     A habit of being truthful even when it hurts

THE FIRM

Revive is a national public relations firm specializing in Health Services and Healthy Living. Named “New Agency of the Year” in 2010 by The Holmes Report and “Best Agency to Work For” in 2011, Revive is the 11th largest health care PR firm in the country. Revive's clients include major hospitals and health care systems, academic medical centers, physician organizations, health care industry associations, health care IT, and health & wellness companies. With 20 professionals on staff, Revive has offices in Santa Barbara, California and Nashville, Tennessee. To learn more, visit www.revivepr.com.

FDA News: Medspira Receives FDA Clearance

Medspira Receives FDA 510K Clearance for mcompass Anorectal Manometry Device.

Full press release below.

SOURCE: Medspira

Makes Testing Practical for a Wide Range of Medical Specialists

MINNEAPOLIS--(BUSINESS WIRE)--Medspira has received U.S. Food and Drug (FDA) 510K clearance for its innovative mcompass anorectal manometry device. Anorectal manometry testing evaluates pelvic floor function in patients with constipation or fecal incontinence.

“Yet, despite the health and lifestyle consequences, only one in 13 patients with fecal incontinence or chronic constipation is tested to determine the cause of their disorder. Often, sufferers are provided a range of treatments that fail to address the root of their problem.”

Incorporating a range of unique features, mcompass is designed to make testing highly accurate, easy to perform and practical for a broad range of medical specialists. In addition to colorectal surgeons and gastroenterologists, Medspira will market the device to primary care physicians, gerontologists, URO/GYNs and OBGYNs.

“Fecal incontinence and related chronic constipation are major medical problems and growing significantly with today’s aging population,” says Jim Quackenbush, CEO of Medspira. “Yet, despite the health and lifestyle consequences, only one in 13 patients with fecal incontinence or chronic constipation is tested to determine the cause of their disorder. Often, sufferers are provided a range of treatments that fail to address the root of their problem.”

Unlike today’s more complex and cumbersome anorectal devices, mcompass is portable, compact and weighs only three pounds. Other systems usually require a cart and dedicated room, while mcompass can be set up anywhere in minutes. Testing can be easily conducted in nursing homes or other community locations.

Intuitive and user-friendly, mcompass comprises three simple components—a disposable catheter, mobile tablet PC and wireless portable manometer. Built-in software prompts guide even inexperienced users through the testing process. The device is ready for use within seconds due to an innovative priming method, and results display in real time on the device’s tablet PC workstation. The full encrypted data packet can be emailed to specialists for interpretation, if needed, in a few clicks using the device’s built-in Wi-Fi connectivity.

In addition, mcompass features an innovative, disposable catheter for enhanced testing accuracy and a proprietary single-connector to streamline set-up. The catheter comprises a central rectal balloon and four radial anal canal balloons at 90 degree relative positioning. Each balloon provides independent measurement. The device’s anal canal balloon is 20 mm long, enabling one or two positioned full anal canal measurements. A non-compliant rectal balloon supports true rectal compliance testing. (Continued: http://www.healthflashmarketing.com/Medspira%20mcompass%20510k%205-21-12.pdf)

Contacts

HealthFlash Marketing
Jeanne-Marie Phillips, 888-655-3434
jphillips@healthflashmarketing.com

Mobile health news, WellnessFX app

WellnessFX has launched its iOS  mobile app, designed to help users build, manage and track their personal health goals. The app allows users to research vitamins and supplements, scan supplements into their plan using a smartphone camera and then track and share their supplement plans with others. Full press release is below. SOURCE: WellnessFX WellnessFX Launches Mobile App -- A 'Better Way to Manage your Health' goes Mobile - Sophisticated Tools to Manage Supplements & Integrative Health Programs - SAN FRANCISCO, May 17, 2012 /PRNewswire/ -- WellnessFX announced today the launch of their iOS  mobile app designed to help users build, manage and track their personal health goals. With the WellnessFX mobile app, users can research vitamins and supplements, scan supplements into their plan using a smartphone camera and then track and share their supplement plans with others. WellnessFX mobile is designed for those new to WellnessFX as well as those already using the company's cloud-based health and wellness platform to manage their health online with advanced predictive diagnostics and personal care teams. WellnessFX collects labs, runs comprehensive analysis, and provides a personal health record with clear markers on areas of concern. Their team of licensed health professionals then reviews the data to deliver personalized insight and actionable recommendations. The app allows one to: Research and understand the use of supplements through a partnership with Aisle7, a leading source of health data Quickly add vitamins and supplements to a personal plan by scanning the barcodes Capture daily activities like supplement use to track progress on a health plan Compare supplement use with RDA (Recommended Daily Allowance) levels to track performance against guidelines See and share the biomarker data from WellnessFX personal health dashboard (for WellnessFX members) Share supplement plan and results to social networks "In exploring ways for everyone to engage with their health, we wanted to create a tool for people to effectively track and measure their supplement use as part of their individual integrative health plan," notes WellnessFX CEO and founder, Jim Kean. "It's a simple and powerful tool to make small changes, which accumulate over time, to better manage your health." The app works in conjunction with the WellnessFX platform, with feedback and engagement on daily activities that results in better health outcomes. WellnessFX offers its customers an alternative healthcare experience by providing online access and phone consultations with physicians and nutritionists powered by data from advanced predictive biomarkers. The platform further promotes engagement by tracking health improvements based on changes made in diet, exercise, lifestyle or supplement intake as suggested by the WellnessFX physician. The mobile app is yet another way WellnessFX makes it easier for people to engage with managing their health data and trends to achieve their personal health goals. "Aisle7 is delighted we're part of the WellnessFX service. They are a very innovative company providing personal data and information in an attractive and useful way to help consumers make healthy decisions based on their own health record," said Dr. Skye Lininger, CEO of Aisle7. "Integrating the Aisle7 sophisticated supplement rating system into the WellnessFX platform, creates the first consumer application that will give individuals direct feedback on the impact of supplements on their health." Silicon Valley VC firms Floodgate, Javelin, and Voyager have backed the companies. Tim Ferriss, internationally renowned author and speaker is an advisor to WellnessFX. For more information, go to: http://www.wellnessfx.com/ About WellnessFX Headquartered in San Francisco, California, WellnessFX is at the forefront of the consumer health revolution. WellnessFX meets the demand for a straightforward, accessible way to manage and understand one's own health. WellnessFX provides easy access to health experts to help its users create personalized wellness roadmaps based on rich, personalized visualizations of leading health diagnostic test results. WellnessFX aggregates the underlying biomarkers of the primary detractors of wellness, including cardiovascular disease, diabetes, metabolic syndrome and obesity. SOURCE WellnessFX CONTACT: Celia Sepulveda of Neighbor Agency, +1-858-337-1326, celia@neighboragency.com, for WellnessFX Web Site: http://www.wellnessfx.com